Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Alzheimer's Disease

  Free Subscription


Articles published in BMJ

Retrieve available abstracts of 25 articles:
HTML format



Single Articles


    February 2024
  1. IACOBUCCI G
    Sixty seconds on . . . Viagra and Alzheimer's disease.
    BMJ. 2024;384:q370.
    PubMed    


  2. DYER O
    Aduhelm: Biogen abandons Alzheimer's drug after controversial approval left it unfunded by Medicare.
    BMJ. 2024;384:q281.
    PubMed    


    October 2023
  3. DALY TP
    Informing consent to antibodies in Alzheimer's disease.
    BMJ. 2023;383:p2350.
    PubMed    


    August 2023
  4. HOWARD R, Kales HC
    New treatments for Alzheimer's disease.
    BMJ. 2023;382:1852.
    PubMed    


    July 2023
  5. IACOBUCCI G
    Donanemab leads to modest slowing of Alzheimer's progression, study finds.
    BMJ. 2023;382:p1659.
    PubMed    


  6. MAHASE E
    Alzheimer's disease: Lecanemab gets full FDA approval and black box safety warning.
    BMJ. 2023;382:p1580.
    PubMed    


    June 2023
  7. POURHADI N, Morch LS, Holm EA, Torp-Pedersen C, et al
    Menopausal hormone therapy and dementia: nationwide, nested case-control study.
    BMJ. 2023;381:e072770.
    PubMed     Abstract available


    March 2023
  8. TANNE JH
    Lecanemab: US Veterans Health Administration will cover cost of new Alzheimer's drug.
    BMJ. 2023;380:p628.
    PubMed    


    January 2023
  9. MAHASE E
    Alzheimer's disease: FDA approves lecanemab amid cost and safety concerns.
    BMJ. 2023;380:p73.
    PubMed    


  10. TANNE JH
    Aduhelm: Approval of Alzheimer's drug was highly unorthodox, finds report.
    BMJ. 2023;380:p6.
    PubMed    


    December 2022
  11. WALSH S, Merrick R, Richard E, Nurock S, et al
    Lecanemab for Alzheimer's disease.
    BMJ. 2022;379:o3010.
    PubMed    


    August 2022
  12. DYER O
    Alzheimer's: Alleged image manipulation in seminal paper casts doubt on leading hypothesis of disease.
    BMJ. 2022;378:o2041.
    PubMed    


    April 2022
  13. DHANA K, Franco OH, Ritz EM, Ford CN, et al
    Healthy lifestyle and life expectancy with and without Alzheimer's dementia: population based cohort study.
    BMJ. 2022;377:e068390.
    PubMed     Abstract available


    March 2022
  14. DYER O
    Long delayed publication of data on Alzheimer's drug Aduhelm leaves questions unanswered.
    BMJ. 2022;376:o808.
    PubMed    


    January 2022
  15. LYTHGOE MP, Jenei K, Prasad V
    Regulatory decisions diverge over aducanumab for Alzheimer's disease.
    BMJ. 2022;376:e069780.
    PubMed    


    December 2021
  16. MAHASE E
    Aducanumab: European agency rejects Alzheimer's drug over efficacy and safety concerns.
    BMJ. 2021;375:n3127.
    PubMed    


    November 2021
  17. HAMILTON F, West C
    Predatory marriage: Doctors can help to spot and prevent this exploitation.
    BMJ. 2021;375:n2906.
    PubMed    


    September 2021
  18. VINOGRADOVA Y, Dening T, Hippisley-Cox J, Taylor L, et al
    Use of menopausal hormone therapy and risk of dementia: nested case-control studies using QResearch and CPRD databases.
    BMJ. 2021;374:n2182.
    PubMed     Abstract available


    August 2021
  19. ILIFFE S, Manthorpe J
    Aducanumab, amyloid, and culture wars.
    BMJ. 2021;374:n2038.
    PubMed    


    July 2021
  20. DYER O
    FDA calls for investigation into industry influence during Alzheimer's drug approval.
    BMJ. 2021;374:n1778.
    PubMed    


  21. WALSH S, Merrick R, Milne R, Brayne C, et al
    Aducanumab for Alzheimer's disease?
    BMJ. 2021;374:n1682.
    PubMed    


    June 2021
  22. MAHASE E
    Three FDA advisory panel members resign over approval of Alzheimer's drug.
    BMJ. 2021;373:n1503.
    PubMed    


  23. MAHASE E
    FDA approves controversial Alzheimer's drug despite uncertainty over effectiveness.
    BMJ. 2021;373:n1462.
    PubMed    


    February 2021
  24. ACKLEY SF, Zimmerman SC, Brenowitz WD, Tchetgen Tchetgen EJ, et al
    Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis.
    BMJ. 2021;372:n156.
    PubMed     Abstract available


    October 2020
  25. SHI J, Sabbagh MN, Vellas B
    Alzheimer's disease beyond amyloid: strategies for future therapeutic interventions.
    BMJ. 2020;371:m3684.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Alzheimer's Disease is free of charge.